Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Xiaoling Wang is a distinguished academic and researcher currently serving as a Professor and Principal Investigator at Guangzhou Medical University since June 2018. With extensive experience as a Senior Scientist at 广州市香雪制药股份有限公司, Xiaoling specializes in developing novel affinity enhanced TCR-T cell therapy and GMP level lentivirus manufacturing. Prior roles include a Scientist at Intrexon Corporation, focusing on genome editing in primary and stem cells, a Research Fellow at City of Hope working on genome editing in human embryonic stem cells, and a Postdoctoral Fellow at UCSF where significant contributions were made in iPS reprogramming. Xiaoling holds a PhD in Pharmacology from the University at Buffalo, alongside degrees in Molecular Virology and Virology from Wuhan University, and a Certificate in Bioscience Management from Keck Graduate Institute.
This person is not in the org chart
This person is not in any teams
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
XPH was founded in 1997 with the mission of "Hou Sheng（厚生），Zhen Shan（臻善）， Wei Xin（维新）,which means caring for mankind, pursuing excellence and striving for innovation. It has been listed on the Shenzhen Exchange (Stock Code: 300147) as Guangzhou Xiangxue Pharmaceutical Co., Ltd since 2011. XPH aims at TCM development and modernization, being the leading enterprise in modern TCM industry with our own intellectual property, brands and innovation. XPH has set up the complete industrial chain, including R&D, procurement, manufacturing, delivering and distribution. Eighteen subsidiaries of XPH was established in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia, etc., employing 10,000 more staff. XPH is an integrated TCM healthcare enterprise with our diversified healthcare portfolio: prepared TCM in pieces, TCM, health solutions (food & beverage), healthcare supplements and so on.